News
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...
Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th